3个月减掉5kg!这款糖尿病新药用来减肥也是牛了
2017/10/28
一个款即将上市的糖尿病重磅新药或许还将成为肥胖人群的“福利”!发表在Diabetes, Obesity and Metabolism杂志上的一项研究证实,平均来说,在接受了每周一次的该药物治疗后,参与者体重显著下降,12周内减掉了5千克。

这款名为“Semaglutide”的糖尿病药物由丹麦制药巨头公司诺和诺德开发。10月18日,公司官网宣布,美国FDA内分泌和代谢药物咨询委员会以“16:0”的投票结果支持批准semaglutide用于改善2型糖尿病成人患者的血糖控制。通常FDA在做出最终审查决定时,都会采纳咨询委员会的建议。这也意味着,该药有望于近期获批上市。

       

图片来源:公司官网

业界对Semaglutide的前景十分看好,认为将帮助诺和诺德在全球糖尿病市场中进一步保持主导地位。更有分析师预测,其有望在2030年达到46-53亿美元的销售峰值。

具体来说,Semaglutide是一种新型长效胰高血糖素样肽-1(GLP-1)类似物,化学结构与天然存在激素GLP-1非常相似。GLP-1被认为是作用于大脑下丘脑中的食欲控制中心以降低饥饿感。考虑到semaglutide与人类自带的是食欲控制化合物非常相似,因此,科学家们开始调查这个药物是否能够通过作用于大脑的食欲控制受体来对抗肥胖。


图片来源:http://onlinelibrary.wiley.com

试验方法

这项新研究共包括28名BMI指数(身体质量指数,体重公斤数除以身高米数平方得出的数字)在30到45之间的参与者。他们被分为两组,一组注射semaglutide,另一组注射安慰剂,但他们都并不知道自己具体被注射了什么。

12周后,这些参与者被邀请到测试中心享用午餐和晚餐。他们被告知可以尽情的吃,直到感觉满足为止,而所吃的东西、食物偏好、体重、体脂等信息会被记录下来。之后,参与者重复上述试验。不过,前一次试验注射semaglutide的参与者这次注射安慰剂,之前接受安慰剂的参与者这次接受semaglutide。

惊人结果

结果显示,semaglutide治疗使得平均每天的能量摄入降低了24%。此外,领导该研究的英国利兹大学的科学家们发现,参与者大部分的体重降低来自体脂肪的减少。


图片来源:网络

论文的第一作者兼通讯作者John Blundell教授说:“这个药物的减肥效果是令人震惊的。我们在12周内看到的减肥‘成绩’,换成其它抵抗肥胖的药物可能需要6个月的时间才能实现。Semaglutide不仅降低了饥饿感,还削弱了对食物的渴望和想吃东西的感觉。先前的理论认为,这些感觉源于大脑的不同部分。”

Blundell教授还认为,能够使每天食物摄入量减少约四分之一的药物将帮助一些人更容易控制他们的生活,同时将帮助预防由肥胖引起的健康问题的发生。

参考资料:

Drug can dramatically reduce weight of people with obesity

Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity

Semaglutidereceives positive 16-0 vote in favour of approval from FDA Advisory Committee

重大消息!诺和诺德新型降糖药semaglutide获美国FDA专家委员会全票通过,兼具降糖、减肥、降低心血管风险三大功效

所有文章仅代表作者观点,不代表本站立场。如若转载请联系原作者。
查看更多
  • Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity

    Abstract Aim The aim of this trial was to investigate the mechanism of action for body weight loss with semaglutide. Materials and methods This randomised, double-blind, placebo-controlled, two-period crossover trial investigated the effects of 12 weeks of treatment with once-weekly subcutaneous semaglutide, dose-escalated to 1.0 mg, in 30 subjects with obesity. Ad libitum energy intake, ratings of appetite, thirst, nausea and well-being, control of eating, food preference, resting metabolic rate, body weight and body composition were assessed. Results After a standardised breakfast, semaglutide, compared with placebo, led to a lower ad libitum energy intake during lunch (−1255 kJ; P  < .0001) and during the subsequent evening meal ( P  = .0401) and snacks ( P  = .0034), resulting in a 24% reduction in total energy intake across all ad libitum meals throughout the day (−3036 kJ; P  < .0001). Fasting overall appetite suppression scores were improved with semaglutide vs placebo, while nausea ratings were similar. Semaglutide was associated with less hunger and food cravings, better control of eating and a lower preference for high-fat foods. Resting metabolic rate, adjusted for lean body mass, did not differ between treatments. Semaglutide led to a reduction from baseline in mean body weight of 5.0 kg, predominantly from body fat mass. Conclusion After 12 weeks of treatment, ad libitum energy intake was substantially lower with semaglutide vs placebo with a corresponding loss of body weight observed with semaglutide. In addition to reduced energy intake, likely mechanisms for semaglutide-induced weight loss included less appetite and food cravings, better control of eating and lower relative preference for fatty, energy-dense foods.

    展开 收起
发表评论 我在frontend\modules\comment\widgets\views\文件夹下面 test